CO7210299A2 - Forma de dosis farmaceútica oral a prueba de manipulación que comprende un agente antagonista y/o repelente opioide, óxido de polialquileno y un polímero aniónico - Google Patents
Forma de dosis farmaceútica oral a prueba de manipulación que comprende un agente antagonista y/o repelente opioide, óxido de polialquileno y un polímero aniónicoInfo
- Publication number
- CO7210299A2 CO7210299A2 CO14077088A CO14077088A CO7210299A2 CO 7210299 A2 CO7210299 A2 CO 7210299A2 CO 14077088 A CO14077088 A CO 14077088A CO 14077088 A CO14077088 A CO 14077088A CO 7210299 A2 CO7210299 A2 CO 7210299A2
- Authority
- CO
- Colombia
- Prior art keywords
- dosage form
- pharmaceutical dosage
- anionic polymer
- repellent agent
- opioid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se relaciona con una forma de dosisfarmacéutica para la administración oral que tiene unaresistencia a la ruptura de por lo menos 300 N y que comprende(i) un ingrediente farmacológicamente activo; (ii) unantagonista opioide y/o un agente repelente; (iii) un óxido depolialquileno que tiene un peso molecular promedio de por lomenos 200,000 g/moles; y (a) comprende (iv) un polímeroaniónico; y/o (b) tiene una estabilidad de almacenamiento a40°C de por lo menos 3 meses.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11009129 | 2011-11-17 | ||
EP12001295 | 2012-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7210299A2 true CO7210299A2 (es) | 2015-03-09 |
Family
ID=47191746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO14077088A CO7210299A2 (es) | 2011-11-17 | 2014-04-09 | Forma de dosis farmaceútica oral a prueba de manipulación que comprende un agente antagonista y/o repelente opioide, óxido de polialquileno y un polímero aniónico |
Country Status (17)
Country | Link |
---|---|
US (1) | US20130129826A1 (es) |
EP (1) | EP2780000B1 (es) |
JP (1) | JP6085307B2 (es) |
KR (1) | KR20140096062A (es) |
CN (1) | CN104066426A (es) |
AR (1) | AR088875A1 (es) |
AU (1) | AU2012338872B2 (es) |
BR (1) | BR112014011504A2 (es) |
CA (1) | CA2855718A1 (es) |
CL (1) | CL2014000904A1 (es) |
CO (1) | CO7210299A2 (es) |
EA (1) | EA201400590A1 (es) |
HK (1) | HK1200742A1 (es) |
IL (1) | IL232054A0 (es) |
MX (1) | MX349725B (es) |
PE (1) | PE20141671A1 (es) |
WO (1) | WO2013072395A1 (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
ES2570454T3 (es) | 2003-03-26 | 2016-05-18 | Egalet Ltd | Sistema de liberación controlada de morfina |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
RU2493830C2 (ru) | 2008-01-25 | 2013-09-27 | Грюненталь Гмбх | Лекарственная форма |
RU2508092C2 (ru) | 2008-05-09 | 2014-02-27 | Грюненталь Гмбх | Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки |
AU2010211220B2 (en) | 2009-02-06 | 2013-08-01 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
BR112012001244A2 (pt) * | 2009-07-22 | 2020-12-08 | Gruünenthal Gmbh | Forma de dosagem resitente à adulteração, seu processo de produção, e embalagem contendo tal forma |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
NZ607392A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising inorganic salt |
AU2011297892B2 (en) | 2010-09-02 | 2014-05-29 | Grunenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
CA2839126A1 (en) | 2011-07-29 | 2013-02-07 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
AR087360A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
WO2013127831A1 (en) | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
LT2838512T (lt) | 2012-04-18 | 2018-11-12 | GrĆ¼nenthal GmbH | Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
CN104684548A (zh) | 2012-07-06 | 2015-06-03 | 埃格勒特有限责任公司 | 防止滥用的控释药物组合物 |
MX362838B (es) * | 2012-07-12 | 2019-02-19 | SpecGx LLC | Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente. |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
EP3003283A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
BR112016000194A8 (pt) | 2013-07-12 | 2019-12-31 | Gruenenthal Gmbh | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila |
CN103304570A (zh) * | 2013-07-12 | 2013-09-18 | 四川省惠达药业有限公司 | 一种盐酸纳洛酮化合物、其制备方法及其药物组合物 |
CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
MX2016008361A (es) * | 2013-12-23 | 2016-10-14 | Purdue Pharma Lp | Formulaciones de antagonista de opioides. |
MX2016014738A (es) | 2014-05-12 | 2017-03-06 | Gruenenthal Gmbh | Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol. |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
EP3174534A1 (en) * | 2014-08-01 | 2017-06-07 | KRKA, d.d., Novo mesto | Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters |
CA2964628A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
EP3229785A2 (de) * | 2014-12-08 | 2017-10-18 | Develco Pharma Schweiz AG | Naloxon-monopräparat und mehrschichttablette |
WO2016170096A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
MX2017013633A (es) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. |
WO2016170093A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
MX2017013637A (es) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes. |
JP2018520165A (ja) * | 2015-07-10 | 2018-07-26 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドSun Pharma Advanced Research Company Limited | ヒドロコドンの多数錠剤乱用抵抗性即時放出型固体投薬形態物 |
DE202016005375U1 (de) * | 2015-09-03 | 2016-09-30 | Acino Pharma Ag | Verminderung der Deallylierung von Naloxon während der Lagerung einer naloxonhaltigen Retardformulierung |
WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
EP3773509B1 (en) | 2018-04-06 | 2023-11-01 | Capsugel Belgium NV | Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)] |
CN115337440B (zh) * | 2022-08-22 | 2024-03-29 | 南通大学 | 一种促进伤口复原的纳米敷料及其制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2059297A (en) * | 1996-03-12 | 1997-10-01 | Alza Corporation | Composition and dosage form comprising opioid antagonist |
ATE493130T1 (de) * | 2001-05-11 | 2011-01-15 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
AU2002321879A1 (en) | 2001-08-06 | 2003-03-03 | Thomas Gruber | Pharmaceutical formulation containing dye |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
LT2425821T (lt) | 2002-04-05 | 2017-07-25 | Euro-Celtique S.A. | Farmacinis preparatas, turintis oksikodono ir naloksono |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US20070048228A1 (en) * | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE502004004205D1 (de) | 2003-08-06 | 2007-08-09 | Gruenenthal Gmbh | Gegen missbrauch gesicherte darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
WO2005102286A1 (de) | 2004-04-22 | 2005-11-03 | Grünenthal GmbH | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform |
PL1765303T5 (pl) | 2004-07-01 | 2023-05-22 | Grünenthal GmbH | Tabletka doustna zabezpieczona przed nadużywaniem |
CA2572352A1 (en) | 2004-07-01 | 2006-01-12 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol |
WO2006002883A1 (de) | 2004-07-01 | 2006-01-12 | Grünenthal GmbH | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
JP5667575B2 (ja) * | 2008-12-16 | 2015-02-12 | パラディン ラブス インコーポレーテッド | 誤用を防止する放出制御製剤 |
GB0909680D0 (en) * | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
AU2011297892B2 (en) * | 2010-09-02 | 2014-05-29 | Grunenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
AU2012219322A1 (en) * | 2011-02-17 | 2013-05-09 | QRxPharma Ltd. | Technology for preventing abuse of solid dosage forms |
AR088250A1 (es) * | 2011-10-06 | 2014-05-21 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide |
-
2012
- 2012-11-15 KR KR1020147013076A patent/KR20140096062A/ko not_active Application Discontinuation
- 2012-11-15 EP EP12787711.6A patent/EP2780000B1/en not_active Not-in-force
- 2012-11-15 CA CA2855718A patent/CA2855718A1/en not_active Abandoned
- 2012-11-15 AR ARP120104298A patent/AR088875A1/es unknown
- 2012-11-15 WO PCT/EP2012/072678 patent/WO2013072395A1/en active Application Filing
- 2012-11-15 BR BR112014011504A patent/BR112014011504A2/pt not_active IP Right Cessation
- 2012-11-15 PE PE2014000627A patent/PE20141671A1/es not_active Application Discontinuation
- 2012-11-15 US US13/677,446 patent/US20130129826A1/en not_active Abandoned
- 2012-11-15 AU AU2012338872A patent/AU2012338872B2/en not_active Ceased
- 2012-11-15 MX MX2014005820A patent/MX349725B/es active IP Right Grant
- 2012-11-15 JP JP2014541653A patent/JP6085307B2/ja not_active Expired - Fee Related
- 2012-11-15 EA EA201400590A patent/EA201400590A1/ru unknown
- 2012-11-15 CN CN201280056414.5A patent/CN104066426A/zh active Pending
-
2014
- 2014-04-09 CO CO14077088A patent/CO7210299A2/es unknown
- 2014-04-10 IL IL232054A patent/IL232054A0/en unknown
- 2014-04-10 CL CL2014000904A patent/CL2014000904A1/es unknown
-
2015
- 2015-02-11 HK HK15101505.9A patent/HK1200742A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013072395A1 (en) | 2013-05-23 |
JP6085307B2 (ja) | 2017-02-22 |
NZ623291A (en) | 2016-01-29 |
MX2014005820A (es) | 2014-06-04 |
AU2012338872A1 (en) | 2014-04-17 |
PE20141671A1 (es) | 2014-11-22 |
JP2014533668A (ja) | 2014-12-15 |
IL232054A0 (en) | 2014-05-28 |
CA2855718A1 (en) | 2013-05-23 |
KR20140096062A (ko) | 2014-08-04 |
AR088875A1 (es) | 2014-07-16 |
HK1200742A1 (en) | 2015-08-14 |
EA201400590A1 (ru) | 2014-11-28 |
CN104066426A (zh) | 2014-09-24 |
CL2014000904A1 (es) | 2014-08-18 |
BR112014011504A2 (pt) | 2017-05-09 |
US20130129826A1 (en) | 2013-05-23 |
MX349725B (es) | 2017-08-10 |
EP2780000B1 (en) | 2019-04-03 |
EP2780000A1 (en) | 2014-09-24 |
AU2012338872B2 (en) | 2017-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO7210299A2 (es) | Forma de dosis farmaceútica oral a prueba de manipulación que comprende un agente antagonista y/o repelente opioide, óxido de polialquileno y un polímero aniónico | |
ECSP14013269A (es) | Forma de dosificación resistente a la alteración comprendiendo agonista opioide y antagonista opioide | |
AR096439A1 (es) | Forma de dosificación resistente al uso indebido que contiene una o más partículas | |
CY1120783T1 (el) | Ανθεκτικη εναντι παραβιασης και ανθεκτικη εναντι μεταποθηκευσης δοσης φαρμακευτικη μορφη δοσολογιας | |
ECSP12011590A (es) | Forma de dosificación de oxidación estabilizada resistente a la manipulación | |
ECSP13012474A (es) | Forma de dosificación resistente a manipulación que comprende una sal inorgánica | |
CY1119637T1 (el) | Θερμοσχηματιζομενη, ανθεκτικη σε αλλοιωση φαρμακευτικη μορφη δοσολογιας που περιεχει ψευδαργυρο | |
CY1119829T1 (el) | Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου | |
CO6670598A2 (es) | Forma de dosificación resistente a alteración que comprende un polímero aniónico | |
ECSP13012472A (es) | Forma de dosificación resistente a alteración que comprende un polímero aniónico | |
MX2015016112A (es) | Forma de dosificacion resistente al uso indebido que contiene una o mas particulas. | |
BR112016001678A2 (pt) | Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária | |
ECSP10010416A (es) | Forma de dosificación farmaceutica | |
IN2014DN08870A (es) | ||
EA201690679A1 (ru) | Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан | |
CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
EA201200485A1 (ru) | Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол | |
CL2013001684A1 (es) | Composicion farmaceutica de administracion oral que comprende alisporivir, un componente lipofilico, un tensoactivo y un componente hidrofilico. | |
UY29403A1 (es) | Composiciones farmacéutica sólida que comprende telitromicina. | |
TR201803451T4 (tr) | Olmesartan formülasyonlari. | |
ECSP14000928A (es) | Forma de dósis farmacéutica oral a prueba de manipulación que comprende un agente antagonista y/o repelente opioide, óxido de polialquileno y un polímero aniónico | |
PH12015501313B1 (en) | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration | |
TR201005911A2 (tr) | Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu. | |
CL2012000499A1 (es) | Forma de dosificación farmacéutica sólida oral de liberación extendida que comprende una formulación matricial de liberación extendida que comprende 5 a 500 mg de clorhidrato de oxicodona y al menos 80 % (p/p) de oxido de polietileno (pm 1.000.000); y su uso para tratar el dolor (div. sol. n° 200702485). |